Bioengineered Tumor-Stroma Prostate Cancer In Vitro Models for Screening Therapeutics.

Cancer-associated fibroblasts are increasingly recognized to have a high impact on prostate tumor growth and drug resistance. Here, we bioengineered organotypic prostate cancer 3D in vitro models to better understand tumor-stroma interplay, the metabolomic profile underlying such interactions, and their impact on standard-of-care therapeutics performance. The assembly of robust and uniform spheroids was evaluated and compared in monotypic PC-3 and heterotypic microtumors comprised of either a healthy or malignant stroma and prostate cancer cells.

"Mannose glycans as key players in trained immunity: A novel anti-tumoral catalyst".

Cell wall glycans isolated from microorganisms are long known to provoke strong immune responses piloted by innate immune cell populations, including monocytes, in the context of Trained Immunity (TI). However, the contribution of yeast-derived mannan in the reprogramming of monocytes remains ill-defined. Here, we demonstrated that TI is often accompanied by an altered gene expression profile of selected glycan-binding proteins expressed by monocytes, including DC-SIGN and Dectin-2.

Metabolic signature of renal cell carcinoma tumours and its correlation with the urinary metabolome.

Introduction: Despite considerable advances in cancer research, the increasing prevalence and high mortality rate of clear cell renal cell carcinoma (ccRCC) remain a significant challenge. A more detailed comprehension of the distinctive metabolic characteristics of ccRCC is vital to enhance diagnostic, prognostic, and therapeutic strategies.

Objectives: This study aimed to investigate the metabolic signatures of ccRCC tumours and, for the first time, their correlation with the urinary metabolome of the same patients.

Current Role of MicroRNAs in the Diagnosis and Clinical Management of Germ Cell Tumors.

Germ cell tumors (GCTs) are a rare and heterogeneous group of neoplasms arising from primitive germ cells. MicroRNAs are small noncoding RNAs that have emerged as potential cancer biomarkers in the last decade. In particular, miR-371a-3p has shown good diagnostic performance for germ cell neoplasia in situ-derived testicular GCTs in several well-established cohorts and is expected to enter the clinical arena in the near future.

Prostate cancer epigenetics - from pathophysiology to clinical application.

Prostate cancer is a multifactorial disease influenced by various molecular features. Over the past decades, epigenetics, which is the study of changes in gene expression without altering the DNA sequence, has been recognized as a major driver of this disease. In the past 50 years, advancements in technological tools to characterize the epigenome have highlighted crucial roles of epigenetic mechanisms throughout the entire spectrum of prostate cancer, from initiation to progression, including localized disease, metastatic dissemination, castration resistance and neuroendocrine transdifferentiation.